Aliskiren

also known as SPP100 · Tekturna · Rasilez · ALISKIREN FUMARATE · Aliskiren fumarate component of amturnide aliskiren hemifumarate · Aliskiren fumarate component of raprazo-hct aliskiren hemifumarate · Aliskiren fumarate component of rasilamlo aliskiren hemifumarate · Aliskiren fumarate component of rasilez-hct aliskiren hemifumarate · +18 more

Small molecule targets REN via inhibition

Developed for: hypertensive disorder · essential hypertension · type 2 diabetes mellitus · heart failure · diabetes mellitus · IgA glomerulonephritis · metabolic syndrome X · chronic kidney disease
+27 more
· congestive heart failure · end stage renal failure · proteinuria · abdominal aortic aneurysm · abdominal obesity-metabolic syndrome · acute coronary syndrome · atherosclerosis · cardiovascular disorder · coronary artery disorder · coronary atherosclerosis · diabetic kidney disease · diabetic macular edema · heart disorder · hypertensive heart disease · idiopathic membranous glomerulonephritis · kidney disorder · Marfan syndrome · myocardial infarction · systolic heart failure · atrial fibrillation · chronic renal failure syndrome · complement 3 glomerulopathy · diastolic heart failure · focal segmental glomerulosclerosis · kidney failure · membranous glomerulonephritis · nephrosclerosis
Investigated by: Novartis · Novartis Pharmaceuticals · Taipei Veterans General Hospital, Taiwan · IRCCS San Raffaele · Medical University of Gdansk · National Taiwan University Hospital
+28 more
· The University of Hong Kong · UMC Utrecht · University of Campania Luigi Vanvitelli · University of Pavia · American Heart Association · Amsterdam UMC, location VUmc · Assaf-Harofeh Medical Center · Beth Israel Deaconess Medical Center · Brigham and Women's Hospital · Chinese University of Hong Kong · Corewell Health East · HeartDrug Research LLC · Kagawa University · Mayo Clinic · Meir Medical Center · National Science and Technology Council, Taiwan · Queen Mary Hospital, Hong Kong · Region Skane · Samsung Medical Center · Sir Mortimer B. Davis - Jewish General Hospital · Texas Tech University Health Sciences Center · The Cleveland Clinic · The Rogosin Institute · The TIMI Study Group · United Christian Hospital · University of Colorado, Denver · Vanderbilt University · Vanderbilt University Medical Center

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	EU (EMA)	Rasilez	—	2007-08-22	europa.eu ↗
Approved	US (FDA)	TEKTURNA	—	2007-03-05	fda.gov ↗

Trials 123 · started per year

today

US approved 2007

EU approved 2007

200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 15 trials
Phase 1	NCT01568775	Jun → Sep 2010	end stage renal failure	Novartis	Completed	No outcome recorded
Phase 1	NCT00424541	Jan → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 1	NCT00416728	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00416468	Nov 2006 → ?	—	Novartis	Completed	No outcome recorded
Phase 1	NCT00223717	Jan 2001 → Jan 2017	hypertensive disorder	Vanderbilt University	Completed	No outcome recorded
Phase 1/24 trials · 2 met primary
Phase 1/2	NCT00834041	Apr 2009 → Jan 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 1/2	NCT00464776	Oct 2005 → Apr 2008	type 2 diabetes mellitus	Novartis	Completed	Met primary
Phase 1/2	NCT00464880	Sep 2005 → Nov 2007	type 2 diabetes mellitus	Novartis	Completed	Met primary
Phase 1/2	NCT00461136	Aug 2005 → Nov 2006	type 2 diabetes mellitus	Novartis	Completed	No outcome recorded
Phase 215 trials · 1 met primary
Phase 2	NCT04183101	Oct 2020 → Dec 2029 expected	C3 glomerulonephritis, dense deposit disease, membranoproliferative glomerulonephritis	Region Skane	Recruiting	No outcome recorded
Phase 2	NCT01480791	Jan 2012 → Dec 2013	diabetes mellitus, hypertensive disorder	Sir Mortimer B. Davis - Jewish General Hospital	Withdrawn	No outcome recorded
Phase 2	NCT01302899	Jan → Dec 2011	—	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT01125514	May 2010 → Aug 2011	heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT01080768	Feb → Nov 2010	hypertensive disorder	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 2	NCT00939588	Jul → Dec 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00923156	May 2009 → Feb 2011	systolic heart failure	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00819767	Feb → Oct 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 2	NCT00768040	Sep 2008 → Feb 2011	diabetic macular edema	Novartis Pharmaceuticals	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT00417170	Oct 2007 → Jul 2010	hypertensive disorder, metabolic syndrome X	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00498433	Jun 2007 → Mar 2012	abdominal obesity-metabolic syndrome, hypertensive disorder	Novartis	Terminated	No outcome recorded
Phase 2	NCT00409578	Feb 2007 → Apr 2009	acute coronary syndrome	Novartis	Completed	No outcome recorded
Phase 2	NCT00097955	Oct 2004 → Apr 2007	diabetic kidney disease	Novartis Pharmaceuticals	Completed	Met primary
Phase 2	NCT00246584	Oct 2004 → ?	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 2	NCT00311012	Aug 2004 → Mar 2005	essential hypertension	Novartis	Completed	No outcome recorded

Phase 350 trials · 7 met primary · 7 missed
Phase 3	NCT01237873	Jan 2011 → Feb 2012	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01259297	Jan 2011 → Nov 2012	—	Novartis Pharmaceuticals	Terminated	Missed primary
Phase 3	NCT01151410	Aug 2010 → Aug 2015	hypertensive disorder	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT01715207	Jun 2010 → Oct 2014	Marfan syndrome	Samsung Medical Center	Completed	No outcome recorded
Phase 3	NCT01150357	Jun 2010 → Aug 2014	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT01113047	May → Oct 2010	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00894387	May 2009 → Aug 2012	congestive heart failure	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00870493	Apr 2009 → Mar 2012	IgA glomerulonephritis	Chinese University of Hong Kong	Completed	No outcome recorded
Phase 3	NCT00853658	Mar 2009 → Oct 2015	heart failure	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00867490	Mar → Aug 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00853827	Mar 2009 → Jan 2013	coronary atherosclerosis	Novartis Pharmaceuticals	Completed	Missed primary
Phase 3	NCT00841672	Jan → Sep 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00797862	Nov 2008 → Nov 2010	essential hypertension	Novartis	Completed	Mixed
Phase 3	NCT00778921	Oct 2008 → Jun 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00765674	Sep 2008 → Aug 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00739973	Sep 2008 → May 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	Met primary
Phase 3	NCT00667719	Jun 2008 → Oct 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00706134	May 2008 → Apr 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00549757	Oct 2007 → Feb 2013	cardiovascular disorder, type 2 diabetes mellitus	Novartis Pharmaceuticals	Terminated	Missed primary
Phase 3	NCT00529451	Sep 2007 → Jul 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00414609	Dec 2006 → Sep 2009	myocardial infarction	Novartis	Completed	Missed primary
Phase 3	NCT00402103	Nov 2006 → Apr 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00387517	Oct 2006 → Aug 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00386607	Oct 2006 → Jul 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00368277	Sep 2006 → Feb 2008	essential hypertension	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00386139	Sep 2006 → Jul 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00344110	Jun 2006 → Apr 2007	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00343551	May 2006 → Jan 2007	essential hypertension	Novartis	Completed	Met primary
Phase 3	NCT00299806	Apr → Nov 2006	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00299832	Apr 2006 → May 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00260923	Nov 2005 → Nov 2006	hypertensive disorder	Novartis	Completed	Met primary
Phase 3	NCT00262236	Nov 2005 → Aug 2006	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219193	Oct 2005 → Jan 2007	essential hypertension	Novartis	Completed	Met primary
Phase 3	NCT00518765	Oct 2005 → Aug 2007	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00219141	Oct 2005 → Nov 2007	essential hypertension, heart disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 3	NCT00171405	Jun 2005 → Feb 2006	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219180	Jun 2005 → Sep 2006	essential hypertension	Novartis	Completed	Met primary
Phase 3	NCT00219102	Jun 2005 → May 2007	diabetes mellitus, essential hypertension	Novartis	Completed	Missed primary
Phase 3	NCT00219011	May 2005 → Feb 2007	heart failure	Novartis	Completed	Met primary
Phase 3	NCT00219167	Apr 2005 → Feb 2006	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219154	Mar 2005 → Jan 2006	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00294710	Mar 2005 → Jul 2006	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219076	Feb → Oct 2005	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219050	Feb → Nov 2005	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 3	NCT00219063	Feb 2005 → Mar 2006	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219115	Jan 2005 → Mar 2006	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219089	Nov 2004 → Aug 2005	—	Novartis	Completed	No outcome recorded
Phase 3	NCT00219128	Nov 2004 → Jun 2005	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219024	Aug 2004 → Jun 2005	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT00219037	Jun 2004 → Oct 2005	essential hypertension	Novartis	Completed	No outcome recorded

Phase 441 trials · 4 met primary · 1 missed
Phase 4	NCT01922141	May 2015 → Jun 2018	hypertensive disorder	Novartis Pharmaceuticals	Withdrawn	No outcome recorded
Phase 4	NCT01570686	Apr → Nov 2012	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01235910	May 2011 → Dec 2012	hypertensive disorder	University of Colorado, Denver	Terminated	No outcome recorded
Phase 4	NCT01368536	May 2011 → Feb 2012	hypertensive disorder, type 2 diabetes mellitus	Novartis Pharmaceuticals	Terminated	No outcome recorded
Phase 4	NCT01138423	Aug 2010 → Feb 2012	hypertensive disorder, metabolic syndrome X	UMC Utrecht	Completed	No outcome recorded
Phase 4	NCT01156207	Jul 2010 → Jul 2013	heart failure	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
Phase 4	NCT01176032	Jun 2010 → Apr 2013	hypertensive disorder, hypertensive heart disease	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT01184599	Jun 2010 → Mar 2013	IgA glomerulonephritis, hypertensive disorder	Kagawa University	Unknown	No outcome recorded
Phase 4	NCT01095822	Mar → Dec 2010	diabetes mellitus	HeartDrug Research LLC	Unknown	No outcome recorded
Phase 4	NCT01060865	Mar 2010 → Oct 2011	hypertensive disorder	Meir Medical Center	Terminated	No outcome recorded
Phase 4	NCT01056731	Feb 2010 → Oct 2011	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT01635387	Feb 2010 → Sep 2012	end stage renal failure, essential hypertension	University of Campania Luigi Vanvitelli	Unknown	No outcome recorded
Phase 4	NCT01070030	Jan → Oct 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT01040494	Jan → Jul 2010	congestive heart failure	National Taiwan University Hospital	Unknown	No outcome recorded
Phase 4	NCT01042392	Nov 2009 → Jan 2011	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT01038895	Nov 2009 → Mar 2010	hypertensive disorder, type 2 diabetes mellitus	University of Pavia	Unknown	No outcome recorded
Phase 4	NCT01048047	Nov → Dec 2009	hypertensive disorder	University of Pavia	Unknown	No outcome recorded
Phase 4	NCT01394770	Sep 2009 → Sep 2012	hypertensive disorder	University of Campania Luigi Vanvitelli	Unknown	No outcome recorded
Phase 4	NCT00994253	Aug 2009 → Dec 2012	hypertensive disorder, type 2 diabetes mellitus	Corewell Health East	Withdrawn	No outcome recorded
Phase 4	NCT00922311	Jul 2009 → Dec 2010	IgA glomerulonephritis	The University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT01150201	Jul 2009 → Aug 2014	kidney disorder	The University of Hong Kong	Completed	No outcome recorded
Phase 4	NCT03115853	Jun 2009 → Jan 2012	hypertensive disorder	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 4	NCT00942994	Jun 2009 → Mar 2010	hypertensive disorder	Novartis	Completed	Met primary
Phase 4	NCT00927394	May 2009 → Oct 2011	essential hypertension	Novartis	Completed	Met primary
Phase 4	NCT01219413	Mar 2009 → Jul 2010	chronic kidney disease, proteinuria	Medical University of Gdansk	Completed	No outcome recorded
Phase 4	NCT00865020	Mar 2009 → Jun 2010	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00853957	Feb → Aug 2009	hypertensive disorder	Novartis	Completed	Met primary
Phase 4	NCT00809926	Jan → Jul 2009	hypertensive disorder	Novartis	Completed	Missed primary
Phase 4	NCT00787605	Nov 2008 → Jan 2010	diabetes mellitus, hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00797316	Nov 2008 → Dec 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00760266	Sep 2008 → Apr 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00765947	Sep 2008 → Aug 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00772577	Aug 2008 → Mar 2009	hypertensive disorder	Novartis	Completed	No outcome recorded
Phase 4	NCT00719316	Jul 2008 → Jul 2009	chronic kidney disease, hypertensive disorder	UMC Utrecht	Unknown	No outcome recorded
Phase 4	NCT00739596	Jul 2008 → Mar 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 4	NCT00660309	Apr 2008 → Dec 2009	type 2 diabetes mellitus	Novartis	Completed	No outcome recorded
Phase 4	NCT00654875	Mar → Nov 2008	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00542269	Mar 2008 → Jul 2009	metabolic syndrome X	Novartis	Terminated	No outcome recorded Stop: Enrollment
Phase 4	NCT00631917	Feb 2008 → Sep 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT00818779	Jan 2008 → Aug 2011	coronary artery disorder, type 2 diabetes mellitus	Texas Tech University Health Sciences Center	Completed	No outcome recorded
Phase 4	NCT00441064	Jan → Nov 2007	hypertensive disorder	Novartis	Completed	Met primary

Phase not applicable8 trials
—	NCT02446548	Mar 2013 → Apr 2014	proteinuria	Medical University of Gdansk	Completed	No outcome recorded
—	NCT01425242	Sep 2011 → Dec 2013	abdominal aortic aneurysm, essential hypertension	Amsterdam UMC, location VUmc	Terminated	No outcome recorded
—	NCT01093781	Nov 2010 → Dec 2011	idiopathic membranous glomerulonephritis	Mayo Clinic	Withdrawn	No outcome recorded
—	NCT01298258	Jul 2010 → Jul 2013	heart failure	Taipei Veterans General Hospital, Taiwan	Unknown	No outcome recorded
—	NCT01252238	Jun 2010 → Dec 2012	—	Brigham and Women's Hospital	Terminated	No outcome recorded
—	NCT01165983	Nov 2009 → Jan 2012	type 2 diabetes mellitus	Beth Israel Deaconess Medical Center	Completed	No outcome recorded
—	NCT00627861	Nov 2008 → May 2010	hypertensive disorder	The Rogosin Institute	Terminated	No outcome recorded
—	NCT00732407	Sep 2008 → Sep 2009	atherosclerosis, type 2 diabetes mellitus	Assaf-Harofeh Medical Center	Unknown	No outcome recorded
Comparator or background therapy31 trials
Phase 1	NCT01217736 Comparator	Sep 2010 → Nov 2011	impaired renal function disease	Vitae Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 1	NCT01103245 Comparator	Mar 2010 → Jul 2012	diabetes mellitus	Vanderbilt University Medical Center	Completed	No outcome recorded
Phase 1	NCT00856960 Comparator	Jan → Mar 2010	hypertensive disorder	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00933920 Comparator	Jun → Dec 2009	hypertensive disorder	Novartis Pharmaceuticals	Completed	No outcome recorded
Phase 2	NCT00881439 Comparator	Apr 2009 → Jul 2012	heart failure, kidney failure	University Medical Center Groningen	Terminated	No outcome recorded
Phase 2/3	NCT01417104 Comparator	Oct 2009 → Dec 2011	atherosclerosis	Ohio State University	Terminated	No outcome recorded
Phase 3	NCT02909166 Comparator	Jan 2012 → Dec 2016	atrial fibrillation	Mika Lehto	Unknown	No outcome recorded
Phase 3	NCT01237223 Comparator	Oct 2010 → May 2011	essential hypertension	Novartis	Completed	No outcome recorded
Phase 3	NCT01318395 Comparator	May 2010 → Jun 2013	hypertensive disorder	University of Erlangen-Nürnberg Medical School	Completed	No outcome recorded
Phase 3	NCT01067326 Comparator	Feb 2010 → Dec 2011	—	Mayo Clinic	Terminated	No outcome recorded
Phase 3	NCT00777946 Comparator	Oct 2008 → May 2009	essential hypertension	Novartis	Completed	Met primary
Phase 3	NCT00705575 Comparator	Jun 2008 → Apr 2009	essential hypertension	Novartis	Completed	No outcome recorded
Phase 4	NCT06718062 Comparator	May 2021 → May 2024	essential hypertension	Hansung University	Completed	No outcome recorded
Phase 4	NCT01893788 Comparator	Apr 2013 → Mar 2016	hypertensive heart disease	Nagoya University	Unknown	No outcome recorded
Phase 4	NCT01827202 Comparator	Dec 2012 → Feb 2016	chronic kidney disease, hypertensive disorder, proteinuria	Medical University of Vienna	Completed	No outcome recorded
Phase 4	NCT01519635 Comparator	Oct 2011 → Oct 2014	hypertensive disorder	Centre Hospitalier Universitaire Vaudois	Completed	No outcome recorded
Phase 4	NCT01461499 Comparator	Oct 2011 → Aug 2014	essential hypertension, type 2 diabetes mellitus	Shiga University	Completed	No outcome recorded
Phase 4	NCT01472796 Comparator	Jul 2011 → Jul 2013	hypertensive disorder	Wayne State University	Unknown	No outcome recorded
Phase 4	NCT01349114 Comparator	Jun 2011 → Jan 2012	diabetes mellitus, hypertensive disorder	University of Alabama at Birmingham	Terminated	No outcome recorded
Phase 4	NCT01409408 Comparator	Apr 2011 → Apr 2013	hypertensive disorder, type 2 diabetes mellitus	Hospital Universitario Pedro Ernesto	Withdrawn	No outcome recorded
Phase 4	NCT01284114 Comparator	Feb 2011 → May 2012	chronic kidney disease, essential hypertension	Jichi Medical University	Completed	No outcome recorded
Phase 4	NCT01305850 Comparator	Jul 2010 → Aug 2011	—	Chulalongkorn University	Unknown	No outcome recorded
Phase 4	NCT01437943 Comparator	Apr 2010 → Jan 2012	chronic renal failure syndrome	Brigham and Women's Hospital	Terminated	No outcome recorded
Phase 4	NCT01541267 Comparator	Dec 2009 → May 2011	chronic kidney disease, proteinuria	Medical University of Gdansk	Completed	No outcome recorded
Phase 4	NCT00949351 Comparator	Sep 2009 → Jul 2010	type 2 diabetes mellitus	Lerdsin General Hospital	Unknown	No outcome recorded
Phase 4	NCT01129557 Comparator	Sep 2009 → Jan 2012	IgA glomerulonephritis, diabetic kidney disease, focal segmental glomerulosclerosis, membranous glomerulonephritis +2	Columbia University	Terminated	No outcome recorded
Phase 4	NCT00974922 Comparator	Aug 2009 → Dec 2011	hypertensive disorder, vitamin D deficiency	UConn Health	Terminated	No outcome recorded Stop: Business
Phase 4	NCT00961207 Comparator	Aug 2009 → Jul 2012	diabetes mellitus, diabetic kidney disease, proteinuria	Cook County Health	Terminated	No outcome recorded
Phase 4	NCT00982033 Comparator	Jul 2009 → Sep 2011	heart failure	Wake Forest University Health Sciences	Completed	No outcome recorded
—	NCT00935064 Comparator	Jun 2009 → Oct 2011	diabetes mellitus	Christiana Care Health Services	Completed	No outcome recorded
—	NCT00773084 Comparator	Sep 2008 → Aug 2009	diastolic heart failure	Texas Tech University Health Sciences Center	Withdrawn	No outcome recorded Stop: Enrollment

Evidence & citations 31 cited values

Every value below carries the sentence it was read from. 158 sources stand behind the page.

Field	Value	Cited text
Known as	aliskiren	“antiproteinuric effect as well as that antihypertensive effect of aliskiren 300 mg / d versus ramipril 10 mg daily” NCT01038895 ↗ 152 “Valturna (aliskiren 150 mg/valsartan 160 mg) tablet” NCT01368536 ↗ “Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg” NCT01237873 ↗ NCT02909166 ↗ NCT00549757 ↗ NCT00344110 ↗ NCT00299806 ↗ NCT00631917 ↗ NCT01129557 ↗ NCT01040494 ↗ NCT00386139 ↗ Show 142 more sources
Known as	ALISKIREN FUMARATE	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of amturnide aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of raprazo-hct aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of rasilamlo aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of rasilez-hct aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of rasitrio aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of sprimeo-hct aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of tekamlo aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of tekturna hct aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren fumarate component of valturna aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren hemifumarate	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren hemifumarate component of amturnide	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren hemifumarate component of tekamlo	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskiren hemifumarate component of valturna	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskirene	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Aliskireno	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Enviage	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	NSC-759185	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Rasilez	“Aliskiren (Rasilez®) is a new antihypertensive drug” NCT01060865 ↗ 1 “aliskiren (Rasilez 300 mg, Novartis Europharm” NCT01541267 ↗
Known as	Riprazo	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	SPP-100B	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	SPP100	“We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18...” PMID 11799102 ↗ Jan 2002 5 “A Multi-center, Open-label Study Assessing the Safety, Efficacy and Pharmacokinetics of 8 Week's Treatment of SPP100 (Aliskiren) Regimen in Hypertensive Patients With Renal Dysfunction” NCT00299832 ↗ “Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension” NCT00344110 ↗ “SPP100 (Aliskiren) Regimen in Patients With Severe Hypertension” NCT00299806 ↗ “SPP100 (aliskiren)” NCT00424541 ↗ NCT00246584 ↗
Known as	Sprimeo	ChEMBL registry synonym — accepted as the source's own label CHEMBL1639 ↗
Known as	Tekturna	“This study will evaluate the effects of Vitamin D replacement and the effects of an approved medication for hypertension, aliskiren (Tekturna), in patients with high blood...” NCT00974922 ↗ 3 “The purpose of this study is to assess the effect of Tekturna (aliskiren), in combination with an ACE and calcium channel blocker in hypertensive patients diagnosed with Type...” NCT00994253 ↗ “Tekturna (Aliskiren), a direct renin inhibitor (DRI) 300 mg by mouth once daily for 9 months” NCT01129557 ↗ “Aliskiren (Tekturna) is a recently FDA-approved potent direct renin inhibitor” NCT01095822 ↗
Known as	Tekturna (aliskiren)	“Tekturna (aliskiren)” NCT01235910 ↗
Known as	Tekturna (Aliskirin)	“Tekturna (Aliskirin)” NCT01472796 ↗
Action	Inhibit	“aliskiren, an oral direct renin inhibitor” PMID 18525041 ↗ Jun 2008
Modality	Small molecule	“Aliskiren is an orally active, non-peptide renin inhibitor.” NCT00627861 ↗
Route	Oral	“aliskiren, an oral direct renin inhibitor” PMID 18525041 ↗ Jun 2008
Target	REN	“the direct renin inhibitor aliskiren” PMID 21659626 ↗ Jun 2011